Acadian Asset Management
ABCL icon

Acadian Asset Management’s AbCellera Biologics ABCL Stock Holding History

Acadian Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,226
Closed -$24K – 1999
2025
Q4 		$24K Buy
+7,226
New +$32.3K ﹤0.01% 1894
2025
Q1 		– Sell
-178,839
Closed -$521K – 1580
2024
Q4 		$521K Buy
178,839
+165,468
+1,238% +$461K ﹤0.01% 1064
2024
Q3 		$34K Buy
+13,371
New +$37K ﹤0.01% 1898
2023
Q2 		– Sell
-6,070
Closed -$45K – 1697
2023
Q1 		$45K Sell
6,070
-224,735
-97% -$2.04M ﹤0.01% 1526
2022
Q4 		$2.33M Buy
230,805
+195,443
+553% +$2.26M 0.01% 647
2022
Q3 		$348K Buy
35,362
+1,169
+3% +$12.8K ﹤0.01% 1086
2022
Q2 		$365K Buy
34,193
+5,070
+17% +$42.9K ﹤0.01% 1064
2022
Q1 		$283K Buy
+29,123
New +$276K ﹤0.01% 1131

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management's ABCL Position: Q1 2026 in Review

Acadian Asset Management sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 7,226 shares — an estimated $24K sold.

Acadian Asset Management first reported a position in ABCL in Q1 2022 and held it in 8 quarters. The position peaked at $2.33M in Q4 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Acadian Asset Management reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 7,226 AbCellera Biologics shares in Q1 2026, an estimated $24K.
  • Acadian Asset Management first reported a position in AbCellera Biologics in Q1 2022 and held it in 8 quarters.
  • Acadian Asset Management's AbCellera Biologics position peaked at $2.33M in Q4 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.